Other News To Note
Wednesday, October 10, 2012
AtheroNova Inc., of Irvine, Calif., said it is supporting an additional preclinical study at the David Geffen School of Medicine at the University of California, Los Angeles, to expand the uses of compounds to regress atherosclerotic plaque under its pending patents.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.